IMARC Group has recently released a new research study titled “United States Precision Medicine Market Size, Share, Trends and Forecast by Product, Technology, Application, End User, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
Market Overview
The United States precision medicine market size reached USD 38.4 Billion in 2024 and is expected to reach USD 43.2 Billion by 2033, growing at a CAGR of 11.7% during the forecast period of 2025-2033. This growth is driven by advancements in genomics, increased healthcare data, AI and machine learning adoption, government support, and the rising prevalence of chronic diseases.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
United States Precision Medicine Market Key Takeaways
- Current Market Size: USD 38.4 Billion (2024)
- CAGR: 11.7% (2025-2033)
- Forecast Period: 2025-2033
- The market is primarily driven by the widespread prevalence of chronic diseases such as cancer and cardiovascular conditions.
- Government programs and investments encourage innovative healthcare solutions and funding for precision medicine.
- Increasing integration of AI and big data analytics in healthcare enables more accurate patient profiling and personalized treatment.
- Direct-to-consumer genetic testing services are improving patient awareness and engagement, fostering market growth.
- Strategic partnerships between research centers and healthcare providers speed translation of research into clinical practice.
- Rising interest in minimizing adverse drug reactions and improving treatment effectiveness stimulates demand for precision medicine.
Sample Request Link: https://www.imarcgroup.com/united-states-precision-medicine-market/requestsample
Market Growth Factors
Genomic and biotechnology advancements will significantly contribute to the growing adoption of personalized healthcare solutions, boosting accurate diagnostics and targeted therapies. These innovations are expected to actively support the expansion of the United States precision medicine market share, strengthening its influence in shaping future treatment approaches. Progress in genomics, bioinformatics, and drug development will lead to increased pharmaceutical investment in precision medicine R&D. Government programs supporting the development and use of precision medicine ease greater investment and further growth by funding new healthcare solutions and supporting the implementation and use of precision medicine in healthcare systems. This way, the ecosystem starts to feed on itself.
Chronic diseases such as cancer, cardiovascular disease, diabetes, obesity, and certain cancers prevail in the US to a rising degree. The U.S. Food & Drug Administration says chronic diseases cause 7 of the 10 leading causes of death in the US. The problem of meeting the needs of the 28 million Americans who smoke cigarettes, in conjunction with the high incidence of diet-related diseases, creates an intrinsic demand for some unique therapeutic approaches that precision medicine is designed to offer.
AI, big data analytics, and digital health platforms can enable precision medicine through creating patient profiles, predicting risk, and helping to tailor treatment recommendations based on patient characteristics and information. More than 60% of healthcare organizations expect to adopt technologies within the next three years, for example, generative AI and predictive analytics. Digital health platforms permit patients to monitor their health metrics. The platforms also permit patients to receive personalized well-being recommendations. Increased capability of diagnosis and early clinical intervention is fueling market growth.
To get more information on this market Request Sample
Market Segmentation
Analysis by Product:
- Consumables: Essential for diagnostic testing, sample collection, and processing, including reagents and test kits that ensure accurate diagnostic functioning.
- Instruments: Include next-generation sequencing (NGS) platforms, PCR machines, and mass spectrometers, crucial for analyzing genetic information and biomarkers.
- Services: Comprise genetic counseling, bioinformatics, data analysis, and laboratory testing that facilitate individualized treatment plan development.
Analysis by Technology:
- Big Data Analytics: Processes large health datasets encompassing genetics and clinical observations to reveal individualized risk and therapy response patterns.
- Bioinformatics: Interprets complex biological data like genetic sequences, helping predict disease risks and optimize personalized treatments.
- Gene Sequencing: Identifies genetic mutations impacting disease susceptibility and drug response, supporting targeted therapy development.
- Drug Discovery
- Companion Diagnostics
- Others
Analysis by Application:
- Oncology: Focuses on personalizing cancer treatments based on individual genetic profiles to improve treatment efficacy and minimize side effects.
- Central Nervous System (CNS): Targets neurological disorders like Alzheimer’s, Parkinson’s, and multiple sclerosis with personalized therapeutic strategies.
- Immunology: Develops personalized immunotherapies for autoimmune diseases and cancer by modulating immune responses.
- Respiratory Medicine
- Infections
- Others
Analysis by End User:
- Hospitals and Clinics: Direct care providers where personalized therapies are administered for improved patient outcomes.
- Diagnostic Centers: Offer genetic screening and diagnostic testing using technologies like NGS and liquid biopsy for treatment decisions.
- Pharma and Biotech Companies: Lead drug development efforts, focusing on targeted therapies tailored to genetic profiles.
- Healthcare IT Firms
- Others
Regional Insights
The Northeast region stands out as a dominant contributor in the United States precision medicine market. It benefits from well-established healthcare infrastructures, top academic institutions, and advanced research facilities, especially in Massachusetts, New York, and Pennsylvania. This region hosts numerous biotechnology companies and medical research centers that drive clinical trials and pioneering personalized treatment innovations. Its robust ecosystem accelerates market growth and adoption of precision medicine solutions.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=20040&flag=C
Recent Developments & News
In 2024, several key developments advanced the U.S. precision medicine market: On October 31, Ataraxis AI launched Ataraxis Breast, an AI-native prognostic and predictive test for breast cancer, with a 30% accuracy improvement and USD 4 Million in seed funding. On October 23, four cancer research organizations started patient enrollment for myeloMATCH, a precision medicine clinical trial targeting AML and MDS. On April 3, Denovo Biopharma announced positive Phase 2b clinical trial results for DB104 in treatment-resistant depression, seeking global partners for further development. On February 19, NIH identified 275 million new genetic variants through the All of Us Research Program, enhancing data diversity.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302